newsfilter
← Latest News
Business Wire·

Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates

Patent provides added depth to Enveric's EVM301 intellectual property portfolio of potential neuroplastogenic molecules for non-hallucinogenic treatment of neuropsychiatric conditions Enveric Biosciences (NASDAQ:ENVB)